Literature DB >> 406039

Clinical observations on sixty-nine cases of in situ carcinoma of the urinary bladder.

G M Farrow, D C Utz, C C Rife, L F Greene.   

Abstract

In the course of screening 35,000 urological outpatients with urine cytological examinations, cytological indication of cancer was found in 106 patients in the absence of a cystoscopically visible bladder tumor. Sixty-nine of the 106 patients have biopsy-proven in situ carcinoma of the bladder, all transitional in type and anaplastic. Follow-up data on effects of therapy are available on 58 patients treated by various means, including total cystectomy, partial cystectomy, transurethral fulguration, intravesical thiotepa, and external radiation. The duration of symptoms before diagnosis was remarkably long, and the prolonged course of the in situ lesion was also noteworthy. Differences in the observed behavior of in situ bladder carcinoma may be due, in addition to differences in host resistance, to the existence of two pathogenetic forms of bladder cancer, one arising in an extensive field of abnormal epithelium and the other developing in a focal area of abnormality.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 406039

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

Review 1.  Carcinoma in situ and treatment options.

Authors:  M Erton; Y Ilker
Journal:  Int Urol Nephrol       Date:  1996       Impact factor: 2.370

2.  Clinical outcome of primary versus secondary bladder carcinoma in situ.

Authors:  Daher C Chade; Shahrokh F Shariat; Ari Adamy; Bernard H Bochner; S Machele Donat; Harry W Herr; Guido Dalbagni
Journal:  J Urol       Date:  2010-06-17       Impact factor: 7.450

3.  Using urine microscopy and cytology for early detection of bladder cancer in male patients with lower urinary tract symptoms.

Authors:  Eddie S Y Chan; Chi-Fai Ng; See-Ming Hou; Sidney K H Yip
Journal:  Int Urol Nephrol       Date:  2010-11-04       Impact factor: 2.370

4.  Clinical outcomes of primary bladder carcinoma in situ in a contemporary series.

Authors:  Daher C Chade; Shahrokh F Shariat; Guilherme Godoy; Caroline J Savage; Angel M Cronin; Bernard H Bochner; S Machele Donat; Harry W Herr; Guido Dalbagni
Journal:  J Urol       Date:  2010-07       Impact factor: 7.450

Review 5.  Invasiveness of transformed bladder epithelial cells.

Authors:  J F Kieler
Journal:  Cancer Metastasis Rev       Date:  1984       Impact factor: 9.264

6.  Stem cell marker-positive stellate cells and mast cells are reduced in benign-appearing bladder tissue in patients with urothelial carcinoma.

Authors:  Björn L Isfoss; Christer Busch; Helena Hermelin; Anette T Vermedal; Marianne Kile; Geir J Braathen; Bernard Majak; Aasmund Berner
Journal:  Virchows Arch       Date:  2014-02-26       Impact factor: 4.064

7.  Treatment of carcinoma in situ of the bladder with doxorubicin (adriamycin).

Authors:  R W Glashan
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

Review 8.  Current concepts of the aetiology, pathogenesis and pathology of bladder cancer.

Authors:  G H Friedell
Journal:  Urol Res       Date:  1978

9.  Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history.

Authors:  Erik Pasin; David Y Josephson; Anirban P Mitra; Richard J Cote; John P Stein
Journal:  Rev Urol       Date:  2008

10.  Utility of a dual immunostain cocktail comprising of p53 and CK20 to aid in the diagnosis of non-neoplastic and neoplastic bladder biopsies.

Authors:  Isil Z Yildiz; Rosemary Recavarren; Henry B Armah; Sheldon Bastacky; Rajiv Dhir; Anil V Parwani
Journal:  Diagn Pathol       Date:  2009-10-14       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.